(Q36830375)

16 August 2017

1 reference

title

Clinical implications of HIV and hepatitis B co-infection in Asia and Africa (English)

1 reference

16 August 2017

1 reference

Christopher J Hoffmann

object named as

Christopher J Hoffmann

series ordinal

1

0 references

Chloe L Thio

series ordinal

2

object named as

Chloe L Thio

1 reference

16 August 2017

1 June 2007

1 reference

Lancet Infectious Diseases

16 August 2017

1 reference

16 August 2017

7

1 reference

16 August 2017

6

1 reference

16 August 2017

402-409

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

16 August 2017

1 reference

7 January 2021

Mortality by cause for eight regions of the world: Global Burden of Disease Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

A mathematical model to estimate global hepatitis B disease burden and vaccination impact.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Survival in patients with HIV infection and viral hepatitis B or C: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Chronic hepatitis B virus infection in Asian countries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Risk factors for horizontal transmission of hepatitis B virus in a rural district in Ghana

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Household clustering and intra-household transmission patterns of hepatitis B virus infection in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

The pattern of childhood hepatitis B infection in two Gambian villages

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Epidemiology of hepatitis B in Europe and worldwide

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Perinatal transmission of hepatitis B virus in Senegal, west Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

HBeAg and anti-hbe detection by radioimmunoassay: Correlation with vertical transmission of hepatitis B virus in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

The e antigen and vertical transmission of hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Prevalence and mother-to-infant transmission of hepatitis viruses B, C, and E in Southern Tanzania

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Prevalence of hepatitis B antigens in human immunodeficiency virus type 1 seropositive and seronegative pregnant women in Zambia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Prevalence of infection with HIV, hepatitis B and C viruses, in four high risk groups in Eritrea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Hepatitis B virus and hiv infections among patients in Mulago hospital.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Seroepidemiology of hepatitis B virus in Addis Ababa, Ethiopia: transmission patterns and vaccine control

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Outcome of Hepatitis B Virus Infection in Homosexual Men and Its Relation to Prior Human Immunodeficiency Virus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

HIV, HBV, delta-agent and Treponema pallidum infections in two rural African areas

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Association of hepatitis B and human immunodeficiency virus infections in Tanzanian population groups

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Evaluation of seroepidemiological associations between HIV-infection, hepatitis B and other sexually transmitted diseases in African patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Accelerated loss of antibody to hepatitis B surface antigen among immunodeficient homosexual men infected with HIV

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Côte d'Ivoire: the ANRS 1236 study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

HIV-1 prevalence and herpes simplex virus 2, hepatitis C virus, and hepatitis B virus infections among male workers at a sugar estate in Malawi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Seroprevalence of human immunodeficiency virus, hepatitis B and C viruses and syphilis infections among blood donors at the Muhimbili National Hospital in Dar es Salaam, Tanzania

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Hepatitis B virus activation among central Africans infected with human immunodeficiency virus (HIV) type 1: pre-s2 antigen is predominantly expressed in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Initial report of a randomised double-blind placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Hepatitis B virus infection: co-infection with hepatitis C virus, hepatitis D virus, and human immunodeficiency virus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Natural history of hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Lack of 'occult' hepatitis B virus infection in HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Occult hepatitis B virus infection and its clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Occult hepatitis B virus infection before and 1 year after start of HAART in HIV type 1-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

The interaction of human immunodeficiency virus infection and hepatitis B virus infection in infected homosexual men.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Interactions between human immunodeficiency virus-1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Hepatitis B virus and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Hepatitis B virus-related cirrhosis: natural history and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

AIDS-associated cancer in developing nations.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Increased hepatocarcinogenic potential of hepatitis B virus genotype A in Bantu-speaking sub-saharan Africans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Clinical and serological variation between patients infected with different Hepatitis B virus genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Clinical significance of hepatitis B virus genotypes, variants, and mutants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Hepatitis B viral genotypes: clinical relevance and molecular characteristics.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Drug-induced liver injury

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Acute liver enzyme elevations in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Reactivation of hepatitis B in an HIV-infected patient with antibodies against hepatitis B core antigen as the only serological marker.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Immune reconstitution in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Findings and benefit of liver biopsies in 46 patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

1 reference

7 January 2021

Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Challenges in therapy of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Treatment algorithm for chronic hepatitis B in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Management of patients co-infected with hepatitis B virus and HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Posttreatment exacerbation of hepatitis B virus (HBV) infection in long-term HBV trials of emtricitabine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Viral features of lamivudine resistant hepatitis B genotypes A and D.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

1 reference

7 January 2021

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Response to hepatitis B immunization by infants exposed to HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Hepatitis B immunization and hepatocellular carcinoma: The Gambia Hepatitis Intervention Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970135-4

7 January 2021

10.1016/S1473-3099(07)70135-4

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17521593